Computational Health

For founders pursuing commercial opportunities predicated on translational science and technology innovations that improve human health and wellness.v

  • All Ventures
  • CDL-Seattle

Sonaro

Sonaro has developed Vaso3D, an AI-powered software suite that transforms conventional 2D ultrasound data of large arteries into detailed 3D models of the vessel wall and underlying pathologies. Vaso3D provides automated, precise analysis of the 3D models, enhancing diagnostic accuracy and speeding up the detection of diseased vessels. Their initial focus addresses stroke risk misclassifications, but their core technology is versatile and can be applied to various other vascular conditions and disease indications.

sonaro-ai.com

CDL Mentor Endorsement
"I volunteered to mentor Sonaro after the fall session. I am impressed with the opportunity the team has identified and the strong progress made with limited resources. They have been thoughtful, coachable and strategic in the use of network connections to advance critical initiatives to gather corroborating clinical data. The team has met with FDA so has a clear regulatory path and continues to advance their thinking (and supporting market research) on their go-to-market strategy. I believe Sonaro can be a strong success." - Greg Bullington, CEO & Co-Founder, Magnolia Medical Technologies

Virasoft

Virasoft is focused on improving digital pathology through AI-powered diagnostic algorithms and workflow solutions. The algorithms analyze pathology slides for cancer detection, automating the process of identifying cancerous cells with greater accuracy, while the workflow solutions streamline lab processes by digitizing and managing data more efficiently. Its primary objective is to address the inefficiencies and subjectivity in pathology laboratories, providing scalable solutions for cancer diagnosis and research.

virasoft.com

CDL Mentor Endorsement
"The Virasoft team has deep domain expertise, strong execution capabilities and a mission-driven approach. Many AI startups begin with the technology and try to fit it to a problem, Virasoft did the opposite—starting with clinical workflows and building solutions that integrate into the daily routines of both pathologists and lab teams. The CDL community should know that this team isn’t just building software—they are reshaping how cancer diagnosis and laboratory performance are managed. Their products cover the entire process from biopsy to final pathology report, They are already being used in over 20 institutions, and their U.S. market entry is being guided with the same level of precision by a leader who has been running the commercial operations for an established player in the pathology market. If the team stays focused on scaling in the US and Virasoft is well-positioned to establish market leadership." - Andrew Thompson, Co-Founder, LifeSpeed

Seven Point One

Seven Point One has developed AlzWIN, an AI-powered dementia screening tool that detects verbal fluency. The screening is performed by speaking to a device for one minute and the AI algorithm then analyzes the voice data using around 20 data points. Having proved its effectiveness, accessibility, and accuracy through multiple clinical trials and real-world projects, the solution is now officially adopted by government-operated dementia centers and insurers in Korea.

sevenptone.com

CDL Mentor Endorsement
"Our portfolio of investments specializes in what I call the New Healthcare Diagnostic Realm. It is our belief that we are entering a new era with more broadly deployed healthcare diagnostics that are (1) much better at earlier detection and discrimination of disease, (2) delivered at much lower costs (perhaps OTC, not just professional or Rx) with (3) rapid results, (4) without expensive or unstable reagents and most likely (5) based on totally new sensing modalities well discriminated by always improving, AI-based algorithms. SevenPointOne (sevenptone.com) fits this model perfectly and appears to potentially be an important player in one of the larger and quite poorly served markets: diagnosing (and thereby best treating) dementia. Their sensing modality (analyzing a patient’s speech patterns) is extremely simple and universal and has received early technical validation. Having already been commercialized in Korea and Japan, it successfully identified 10,000 previously undetected dementia patients and secured strong distribution partnerships in both markets. With this solid foundation, early clinical pilots in the US are afoot through collaborations with key industry players and clinics. Notably, a US insurance billing code for their product is already in place, further streamlining its path to adoption. The impact of a SevenPointOne success will change lives for the better worldwide." - Erik Jansen, Managing Partner, Jansen Remmers Nichols and Bernier, inc.

Remmie

Remmie offers an AI-powered ear-nose-throat health platform including diagnostic-enabling at-home otoscopes for providers and patients to avoid unnecessary in-person visits and costs (incl. ER, specialty referrals, chronic recurring monitoring). The Remmie diagnostic assistance AI powers data service for clinicians and at-home App for patients. The platform supports hybrid care and integrates easily with any provider for remote assessments, currently for over 1,800 accounts and can expand to over 35 million users in the US alone.

remmiehealth.com

CDL Mentor Endorsement
"Remmie has done an exceptional job building the foundation of their business with primarily non-dilutive funding. The team has adeptly collected market-based feedback and incorporated into both their hardware and software strategy. The market need to the technology is very clear and the expertise of the founder in the diagnostics space clearly drives a thoughtful and informed product/technology roadmap. The company has important and exciting near-term milestones to achieve that I look forward to supporting as I can as a mentor." - Greg Bullington, CEO & Co-Founder, Magnolia Medical Technologies

Proteotype Diagnostics

Proteotype Diagnostics is an AI-powered cancer detection platform designed for early screening using a simple blood test. The technology detects multiple cancers by analyzing the host's biological response to tumor development, enabling earlier intervention. Unlike current screening methods, which detect only 6% of new cases and leave 70% of cancer deaths from unscreened cancers, Proteotype’s approach aims to transform outcomes by improving survival rates and reducing treatment costs.

proteotype.com

Informuta

Informuta develops RESISENSE, a diagnostic platform that uses machine learning and Next-Generation Sequencing (NGS) to analyze bacterial DNA. It uniquely predicts both current and future antibiotic resistance, allowing for more precise treatment decisions. This technology is designed to improve patient outcomes by enabling faster, more accurate diagnostics and providing prognostics for the first time.

informuta.com

CDL Mentor Endorsement
"Informuta stands out as an inspiring venture because it is pioneering AI-powered DNA analytics to tackle one of healthcare’s most urgent crises: antibiotic resistance. Their RESISENSETM platform not only detects current drug resistance but is the first to predict future resistance, providing clinicians with actionable insights days faster than current diagnostics and potentially saving hospitals millions in avoidable costs. With pre-existing clinical validation data and publications, intellectual property protection, and a scalable SaaS model, Informuta can help transform infectious disease management and data-driven medicine. CEO Kalen Hall, PhD is a recognized expert in mutational signatures—and supported by top scientific and clinical advisors. She is very hard working, driven and extremely coachable. She has secured partnerships with leading medical centers for her company, demonstrating strong early traction, and is forging a path to commercialization." - Barbara Zehentner, COO, Molecular Testing Labs

ModernVivo

ModernVivo is building literature review software tailored for in-vivo scientists, enabling them to reduce costs, accelerate timelines, and enhance translational success. ModernVivo automates the manual processes of searching for and reviewing literature, a critical blocker of study throughput that leads to lost revenue and higher operational costs within pharmaceutical companies and contract research organizations. Think LexisNexis for in-vivo research.

modernvivo.com

MindMirror, Inc.

MindMirror is a SaaS-based platform that leverages artificial intelligence to perform a 7-second test using your mobile phone to determine if someone has experienced a concussion/mTBI. MindMirror then can monitor the recovery process to determine when it is safe to return to activity.

mindmirror.health

CDL Mentor Endorsement
"I was originally inspired to raise my hand for this venture after going through their materials and then working with them in the first small group discussion of the cohort. Even though they were early in their journey, their differentiation from competitors was intriguing. Glenn, being a seasoned executive, was very well prepared and also very open to feedback and mentor suggestions. He was organized and, following the first session, optimized his time with the mentors to gain traction towards completing his objectives. I was impressed by Glenn's ability to set realistic and achievable, yet stretch goals for his objectives and then his ability to execute on them. I feel that this company and team have huge potential to make significant contributions towards brain injury detection in numerous verticals and is exemplary of CDL's mission to support companies who are building something massive." - Buffy Algeria, Managing Partner, LOUD Capital

AffableBPM Corporation

AffableBPM is an AI-powered SaaS platform transforming operational compliance in healthcare, one of the last frontiers of digital transformation.Particularly in mid-sized hospitals and rural clinics, non-clinical back-office operations remain largely manual while technology has advanced on clinical side. AffableBPM unlocks this greenfield market with configurable, no-code workflows that cut administrative costs, eliminate silos, and accelerate audit approvals by up to 75%, hence closes gaps to protect 35–40% of Medicare/Medicaid related provider revenue; enabling staff to focus on patient care instead of paperwork.

affablebpm.ai

CDL Mentor Endorsement
"A repeatable solution that can be sold across multiple mid-sized providers and payors Back-office focused (less regulation) with fast time to deploy (2-5 weeks) and time to value (10-15 weeks) Configurable with prebuilt initial workflows that land and expand at the customers pace, linked with a pay-as-you-use model means customer LTV is high Over $400k ARR already, with good customer names and proof-points Key challenge is about scaling out the GTM, the product is well-designed from concept  Leadership team is strong, with technically deep CEO and subject matter expert co-founder." - Neil Jordan, Strategic Advisor, Former Microsoft

Biocurie

BioCurie is developing a scalable AI-driven platform to optimize the manufacturing of cell, gene, and nucleic acid therapies (CGTs). The platform uniquely combines mechanistic modeling with AI to address production challenges such as cost, speed, and quality in CGT manufacturing. This integration allows biopharmaceutical companies to significantly improve speed, quality, affordability, and patient access to lifesaving gene medicines for patients. The flexible modular nature of the platform means that new modalities (viral gene therapy, cell therapy, RNA, DNA, regenerative medicine, etc.) can be added to the platform as new modules, allowing the BioCurie Platform to expand and evolve as new therapeutic modalities are developed, thereby adding new revenue streams.

biocurie.com

Other Streams